Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Rheumatology

Managing Your Treatment: Options and Strategies for EF

At a Glance

The primary goal of Eosinophilic Fasciitis (EF) treatment is to quickly stop inflammation and prevent permanent joint stiffness. First-line therapy typically involves high-dose corticosteroids, often combined with methotrexate. Early physical therapy is essential to maintain range of motion.

Treatment for Eosinophilic Fasciitis (EF) is focused on two main goals: cooling down the intense inflammation in the fascia and preventing long-term stiffness that can freeze your joints. Getting the correct diagnosis allows your doctor to immediately deploy powerful medications to stop the disease in its tracks [1][2].

First-Line: The Standard of Care

The cornerstone of EF treatment is systemic corticosteroids (such as prednisone) [1][3].

  • High-Dose Induction: Doctors often start with a high dose to “knock down” the inflammation quickly. When starting steroids, many patients notice a significant reduction in deep muscle pain and swelling within the first few weeks, though the skin hardening takes much longer to soften. In the meantime, ask your doctor about safe over-the-counter pain relievers or the use of gentle heat to manage daily discomfort.
  • Pulse Therapy: In some severe cases, treatment may begin with “pulse therapy,” where high doses of methylprednisolone are given through an IV for several days [1][4]. This may be done during a brief hospital stay or at an outpatient infusion center.
  • Combination Therapy: Because steroids have significant side effects when used long-term, many specialists add methotrexate—an immunosuppressive medication—early in the process [5][6]. This is known as a “steroid-sparing” strategy; it helps control the disease so the steroid dose can be lowered more quickly [5].

Managing Medication Side Effects

The medications used to treat EF are powerful and require careful monitoring:

  • Corticosteroids: Long-term use can affect bone density, elevate blood sugar, impact sleep and mood, and increase infection risk. Your doctor will likely recommend calcium and Vitamin D supplements to protect your bones.
  • Methotrexate: This medication requires regular blood tests to track your liver enzymes. You will also need to take a daily folic acid supplement to prevent deficiencies, and you must strictly avoid alcohol to protect your liver.

Treatment for Refractory (Stubborn) Cases

If the initial combination of steroids and methotrexate does not bring the disease under control, your medical team may move to “second-line” or advanced therapies:

  • Rituximab: A medication that depletes B-cells (a type of immune cell) and has shown success in cases where standard drugs failed [7].
  • Infliximab: A “TNF-inhibitor” that blocks a specific protein causing inflammation; it has been effective for some patients with severe or persistent EF [8].
  • Mycophenolate Mofetil (MMF): Another immunosuppressant that can be used to help calm the immune system and reduce skin thickening [9][10].
  • (Note: In exceedingly rare and extreme cases where multiple therapies fail, experimental options like stem cell transplants have been explored, but this is almost never necessary for the vast majority of patients [11].)

Specialized Care: Immunotherapy-Induced EF

If your EF was triggered by immune checkpoint inhibitors (cancer medications like pembrolizumab or nivolumab), your treatment plan might look a little different [12][13].

In some cases, simply pausing or stopping the cancer drug may allow the EF symptoms to reverse [14][15]. However, your doctors will balance the need to treat the EF with the need to keep your cancer under control. Some patients are able to continue their cancer therapy while using low-dose steroids to manage the skin changes [15][16].

Protecting Your Mobility

Regardless of which medication you use, physical therapy is a critical part of avoiding long-term complications [17][2]. As the fascia thickens, it can act like a tight sleeve around your joints, leading to contractures (where a joint becomes permanently stuck in a bent position) [18].

Starting gentle stretching and range-of-motion exercises early—ideally as soon as you begin medication—is essential for maintaining your ability to move your arms and legs freely [2][19].

Common questions in this guide

What are the standard first-line treatments for Eosinophilic Fasciitis?
The primary treatment for EF usually involves high-dose systemic corticosteroids, such as prednisone, to quickly reduce deep muscle pain and swelling. Many doctors also add an immunosuppressant like methotrexate early on to help lower the required steroid dose.
Why is physical therapy important for Eosinophilic Fasciitis?
Physical therapy is critical to prevent contractures, a complication where joints become permanently stuck in a bent position due to tightening fascia. Starting gentle stretching and range-of-motion exercises early helps maintain your ability to move your limbs freely.
How is Eosinophilic Fasciitis treated if it was caused by cancer immunotherapy?
If your condition was triggered by cancer immunotherapy medications, your doctor may temporarily pause the drug to allow symptoms to improve. In other cases, patients can safely continue their cancer treatment while taking low-dose steroids to manage the EF symptoms.
What happens if standard Eosinophilic Fasciitis treatments do not work?
If standard treatments fail to control the inflammation, doctors may move to advanced therapies. These can include biologic medications like Rituximab or Infliximab, or other strong immunosuppressants like Mycophenolate Mofetil to help calm the immune system.
How can I protect my bones while taking steroids for Eosinophilic Fasciitis?
Because long-term corticosteroid use can negatively affect bone density and increase the risk of osteoporosis, your doctor will likely recommend taking daily calcium and Vitamin D supplements to help protect your bones during treatment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What dose of prednisone or methylprednisolone am I starting on, and how long do you expect the 'high-dose' phase to last?
  2. 2.What are the specific side effects I should watch for with my prescribed medications, and what lab tests will we use to monitor my safety?
  3. 3.Should I take calcium and Vitamin D to protect my bones while on steroids?
  4. 4.Is it appropriate to add methotrexate or another 'steroid-sparing' agent early in my treatment to help reduce my overall steroid use?
  5. 5.If my symptoms were triggered by my cancer immunotherapy, should we pause that medication or can we treat the EF while I continue my cancer therapy?
  6. 6.Can you refer me to a physical therapist who has experience working with scleroderma-like conditions?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Eosinophilic fasciitis.

    Lamback EB, Resende FS, Lenzi TC

    Anais brasileiros de dermatologia 2016; (91(5 suppl 1)):57-59 doi:10.1590/abd1806-4841.20164683.

    PMID: 28300895
  2. 2

    Juvenile eosinophilic fasciitis: three case reports with review of the literature.

    Papa R, Nozza P, Granata C, et al.

    Clinical and experimental rheumatology 2016; (34(3)):527-30.

    PMID: 27268780
  3. 3

    Eosinophilic fasciitis: an atypical presentation of a rare disease.

    Cabral C, Novais A, Araujo D, et al.

    Revista da Associacao Medica Brasileira (1992) 2019; (65(3)):326-329 doi:10.1590/1806-9282.65.3.326.

    PMID: 30994827
  4. 4

    Lessons of the month 2: Connecting the clues: limb swelling and pain.

    Prossor T, Sriskandarajah K, Vonberg FW, Dani M

    Clinical medicine (London, England) 2020; (20(1)):105-106 doi:10.7861/clinmed.2019-0293.

    PMID: 31941742
  5. 5

    Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission.

    Tull R, Hoover WD, De Luca JF, et al.

    Drugs in context 2018; (7()):212529 doi:10.7573/dic.212529.

    PMID: 30302114
  6. 6

    Diagnosis and treatment of early eosinophilic fasciitis: a case report.

    Ma J, Cai Y, Shao H, et al.

    Journal of medical case reports 2025; (19(1)):373 doi:10.1186/s13256-025-05440-7.

    PMID: 40731023
  7. 7

    Rituximab for refractory eosinophilic fasciitis: a case series with long-term follow-up and literature review.

    Kougkas N, Bertsias G, Papalopoulos I, et al.

    Rheumatology international 2021; (41(10)):1833-1837 doi:10.1007/s00296-021-04887-3.

    PMID: 34009397
  8. 8

    Refractory eosinophilic fasciitis successfully treated with infliximab: A case report.

    Śmigielska P, Czarny J, Kowalski J, et al.

    Journal of scleroderma and related disorders 2021; (6(2)):211-213 doi:10.1177/23971983211004399.

    PMID: 35386741
  9. 9

    Treatment and Monitoring of Eosinophilic Fasciitis.

    Selva-O'Callaghan A, Trallero-Araguás E, Gil-Vila A, et al.

    Current treatment options in rheumatology 2025; (11()) doi:10.1007/s40674-024-00222-6.

    PMID: 40115529
  10. 10

    Mycophenolate mofetil and mycophenolic acid for the treatment of eosinophilic fasciitis: report of two cases and literature review.

    Moreno-Arquieta IA, Cardenas-de la Garza JA, Esquivel-Valerio JA, et al.

    The Journal of dermatological treatment 2022; (33(3)):1765-1768 doi:10.1080/09546634.2021.1890682.

    PMID: 33615948
  11. 11

    Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation.

    Sasaki K, Popat U, Jain P, et al.

    Clinical case reports 2016; (4(8)):765-7 doi:10.1002/ccr3.613.

    PMID: 27525080
  12. 12

    Eosinophilic Fasciitis in a 78-Year-Old Man Following Pembrolizumab Treatment for Bladder Cancer.

    Oke I, Lenert A, Swick BL, Lenert P

    The American journal of case reports 2025; (26()):e948323 doi:10.12659/AJCR.948323.

    PMID: 41016045
  13. 13

    Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.

    Boppana SH, Dulla NR, Beutler BD, et al.

    The American journal of case reports 2021; (22()):e932888 doi:10.12659/AJCR.932888.

    PMID: 34403405
  14. 14

    Complete reversibility of pembrolizumab-induced eosinophilic fasciitis without corticosteroids: A case report.

    Bourcier L, St-Hilaire È, LeBlanc M, Picard L

    SAGE open medical case reports 2021; (9()):2050313X211025111 doi:10.1177/2050313X211025111.

    PMID: 34178352
  15. 15

    Eosinophilic fasciitis induced by nivolumab therapy managed without treatment interruption or systemic immunosuppression.

    Bui AN, Nelson CA, Lian CG, et al.

    JAAD case reports 2020; (6(8)):693-696 doi:10.1016/j.jdcr.2020.04.010.

    PMID: 32715051
  16. 16

    Nivolumab-Induced Fasciitis Mimicking Scleroderma: A Diagnostic Challenge.

    Jannat R, Kshatri M, Thapa R

    Cureus 2025; (17(8)):e90484 doi:10.7759/cureus.90484.

    PMID: 40978900
  17. 17

    A difficult diagnosis of eosinophilic fasciitis: A case report.

    Mihailescu M, Abbas M

    SAGE open medical case reports 2024; (12()):2050313X241231384 doi:10.1177/2050313X241231384.

    PMID: 38665934
  18. 18

    Groove Sign in Eosinophilic Fasciitis.

    Mourad AI, Lehman JS, Mydlarski PR

    Mayo Clinic proceedings 2021; (96(8)):2184 doi:10.1016/j.mayocp.2021.04.001.

    PMID: 34353471
  19. 19

    Eosinophilic fasciitis difficult to differentiate from scleroderma: A case report.

    Lan TY, Wang ZH, Kong WP, et al.

    World journal of clinical cases 2023; (11(13)):3092-3098 doi:10.12998/wjcc.v11.i13.3092.

    PMID: 37215414

This page provides educational information about Eosinophilic Fasciitis (EF) treatment options and strategies. Always consult your rheumatologist or prescribing physician before making any changes to your medication or physical therapy routine.

Get notified when new evidence is published on Eosinophilic fasciitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.